Qtrilmet – The New Medicine To Treat Diabetes
Qtrilmet is a new medicine used to treat diabetes and contains three active substances: metformin, saxagliptin and dapagliflozin. This medicine is often prescribed as a treatment for patients with type 2 diabetes who cannot adjust their blood sugar levels with simple metformin or in combination with saxagliptin or dapagliflozin. Qtrilmet is also used in diabetic patients who take sulphonylurea and cannot adjust their blood sugar level.
The mechanism of action of the drug Qtrilmet
Glucose levels rise when you have diabetes. The good news is that you can treat yourself with Qtrilmet. As mentioned above, this medicine contains three active ingredients and each of them fulfills a specific function:
- Metformin. This ingredient decreases glucose production and absorption.
- Saxagliptin. The function of this ingredient is to block the activity of hormones released after a meal, so that the pancreas begins to produce insulin. When this blockage occurs, saxagliptin causes the pancreas to produce more insulin as blood sugar levels rise. In addition, this active ingredient helps to reduce the amount of glucose produced in the liver.
- Dapagliflozin. This active substance blocks a kidney protein called the sodium-glucose cotransporter 2 (SGLT2). This protein prevents the passage of blood sugar in the urine and its elimination. When dapagliflozin works, it promotes the passage of glucose into the urine so that it can be eliminated, thus reducing blood sugar levels.
The benefits of Qtrilmet
The combination of metformin, saxagliptin and dapagliflozin is useful because it lowers blood sugar in patients with type 2 diabetes. The variation in glycosylated hemoglobin (HbA1c) levels after six months of treatment is significant. This hemoglobin is a reliable indicator of blood sugar.
HbA1c levels in diabetic patients are usually over 8%. For this reason, the goal of treatments is to reduce them to at least 7%. Overall, Qtrilmet achieves a reduction in HbA1c levels by 0.51%.
In some studies, researchers found that Qtrilmet reduced the average level of HbA1c by 0.82%, compared to patients who did not take this drug and who saw a reduction of only 0.10%.
